IMVT
Immunovant, Inc.
Nasdaq: IMVT · Durham, NC · Healthcare
$39.25+0.13 (+0.33%)Closed
Market Cap$8.10B
Cash$797.8Mmost recent
Runway19 mo$124.4M Q burn
P/E (TTM)—EPS $-2.77
52-Wk Range$14.78 – $44.96
Avg Volume1.6M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$39.25+16.7%
Pipeline
Drug candidates sponsored by Immunovant · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Batoclimab 680 mg SC weekly | Generalized Myasthenia Gravis | Active, not recruiting | 2025-01-10past | 1 | |
| Phase 3 | Batoclimab | Thyroid Eye Disease+1 more | Completed | 2026-07-16past | 4 | |
| Phase 3 | IMVT-1402 | Generalized Myasthenia Gravis+5 more | Recruiting | 2026-10 | 7 | |
| Phase 2 | RVT-1401 | Graves' Ophthalmopathy+1 more | Completed | 2020-10-07past | 2 | |
| Phase 2 | RVT-1401 (Administered via subcutaneous injection) | Graves' Ophthalmopathy (GO) | Terminated | 2021-02-02past | 1 | |
| Phase 2 | RVT-1401 680 mg/weekly | Warm Autoimmune Hemolytic Anemia | Terminated | 2021-04-01past | 1 | |
| Phase 2 | IMVT-1401 (batoclimab) | Graves Disease | Completed | 2025-07-25past | 1 | |
| Phase 2 | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Chronic Inflammatory Demyelinating Polyneuropathy | Terminated | 2026-07-20past | 1 | |
| Phase 2 | Imeroprubart | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | 2028-08 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for IMVT. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.